RTOG Foundation Study 3504
Status Date: September 27, 2018 | Status: Terminated
Safety Evaluations of Nivolumab (Anti-PD-1) Added to Chemoradiotherapy in Patients with Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma
Maura Gillison, MD, PhD
Robert Ferris, MD, PhD
To evaluate the safety of the addition of nivolumab (anti-PD-1 targeted immumotherapy) to cisplatin-based CRT, cextuximab-based CRT or RT alone in patients with intermediate or high-risk head and neck squamous cell carcinoma (HNSCC).
Histologically or cytologically confirmed intermediate- or high-risk HNSCC.
|Inova Fairfax Hospital
|MD Anderson Cancer Center
|Providence Portland Medical Center
|Ohio State University
|University Hospitals Cleveland Medical Center
|University of Florida Health Cancer Center
|University of Louisville
|University of Wisconsin Hospital and Clinics
|UPMC - Shadyside Hospital